Xenon Pharmaceuticals Shares Insights at CNS Therapeutics Conference
Xenon Pharmaceuticals Participation at CNS Therapeutics Conference
Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a notable name in neuroscience-focused biopharmaceuticals, has recently announced its involvement in the highly anticipated BofA Securities 2024 CNS Therapeutics Virtual Conference. This event is scheduled for October 7, 2024, and is set to showcase critical developments and innovations in the field of central nervous system therapeutics.
Key Presentation Details
The conference will include a fireside chat featuring Xenon Pharmaceuticals, where executives will discuss the company’s pipeline and advancements aimed at significantly enhancing patient care. The presentation is particularly noteworthy for those interested in neurological and psychiatric disorders.
Date and Time Highlights
The fireside chat is scheduled for Monday, October 7, 2024, at 11:40 am Eastern Time. Interested participants can access the event through a live webcast available on the Investors section of Xenon's official website. This platform ensures that both attendees and stakeholders can engage with the company's insights and progress.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals is driven by a mission to discover, develop, and distribute innovative therapeutics that improve the lives of individuals facing complex neurological challenges. The company is focused on addressing significant unmet medical needs, particularly in areas like epilepsy and depression.
Innovative Product Pipeline
One of Xenon’s leading candidates is Azetukalner, a groundbreaking Kv7 channel opener. This product stands out as a clinically validated potassium channel modulator and is currently in late-stage clinical development for multiple indications. Through such innovations, Xenon is paving the way for new treatment modalities that could transform patient outcomes in neurology.
Company Commitment
Xenon Pharmaceuticals remains committed to advancing research and development efforts aimed at unveiling novel therapeutic options for patients enduring neurological disorders. Their innovative spirit continues to drive various projects that seek to improve patient care and healing in the realm of neuroscience.
Company Leadership and Impact
The leadership at Xenon is comprised of experienced professionals dedicated to steering the company toward breakthrough achievements in therapeutic interventions. As the company progresses, it aims to deliver solutions that meet the urgent requests of healthcare providers and patients alike.
Contact Information
For those wanting to connect with Xenon’s team, contact details are as follows: For investors, reach out to Chad Fugere, Vice President of Investor Relations, at (857) 675-7275 or via email. Media inquiries can be directed to Colleen Alabiso, Senior Vice President of Corporate Affairs, at (617) 671-9238.
Frequently Asked Questions
What is the focus of Xenon Pharmaceuticals?
Xenon Pharmaceuticals specializes in developing innovative therapeutics for neurological and psychiatric disorders.
When is Xenon Pharmaceuticals participating in the CNS Therapeutics conference?
The company will present on October 7, 2024, at the BofA Securities Virtual Conference.
What is Azetukalner?
Azetukalner is Xenon's lead Kv7 channel opener, currently in late-stage clinical development for multiple indications.
How can I watch the Xenon presentation?
The presentation will be available via live webcast on the Investors section of Xenon’s website.
Who should I contact for investor relations at Xenon?
Chad Fugere is the appropriate contact for investor inquiries at Xenon Pharmaceuticals.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Robertshaw Emerges from Chapter 11 with Renewed Growth Strategy
- USPACE Technology Group's Strategic Board Transitions and Logo Update
- Navigating All-Time Highs: S&P 500 Investment Insights
- Humana Inc. Faces Investigation, What Investors Should Know
- Exploring the Impact of Velocity Commercial Capital's Ratings
- Investors Alert: AMMO Incorporated Faces Securities Class Action
- Lenders Cooperative Names Stephen Hayes as Data Strategy Leader
- Empowering Unity: Highlights from the Texas Women's Conference
- Empowering Financial Literacy in Alabama with Operation HOPE
- New Addiction Treatment Facility Launches in Oklahoma City
Recent Articles
- Spero Therapeutics Presents SPR720 Data at Upcoming Event
- Heritage Commerce Corp Welcomes New COO Thomas A. Sa
- Innventure LLC and Learn CW Successfully Merge to Transform Tech
- Tesla's Q3 Delivery Report: Mixed Signals in the EV Market
- Polu Kai Services Secures Major Medical Facilities Contract
- Xenon Pharmaceuticals to Showcase Innovations in Virtual Conference
- Olema Oncology Expands Employee Incentives with Stock Options
- Olema Oncology Announces Inducement Grants for Employees
- Top Cannabis Stock Moves: Gainers and Losers Insights
- Spero Therapeutics Shares Breakthrough Phase 1 Data on SPR720
- Bullish Trends Highlight Unusual Options Activity for MRNA
- Comstock Inc. Unveils Insights from 3Q24 Stakeholder Analysis
- Glacier Bancorp, Inc. Prepares for Upcoming Earnings Call
- Understanding Accenture's Options Activity and Market Trends
- Golden Ocean Group Announces Extension of Share Buy-Back Program
- A Deep Dive into Zscaler's Recent Option Trading Insights
- Greif Celebrates Recognition as a Leading Workplace for 2024
- Biden's Strategic Oil Trade: A Bold Move for Energy Security
- Insights into Cellectis Voting Rights and Shareholder Information
- Invitation Homes Sharing Q3 2024 Results & Conference Details
- Plains All American Pipeline's Q3 2024 Distributions Explained
- Primaris REIT Announces Major Offering for Strategic Growth
- Ryan Specialty to Reveal Q3 Financial Highlights Soon
- Heritage Commerce Corp Welcomes Thomas A. Sa as New COO
- Top 20 Most-Searched Tickers of September: Insights Unveiled
- CF Industries Announces Dividend and Upcoming Earnings Call
- Ameresco Unveils Largest Landfill Gas to Renewable Natural Gas Facility
- Ecolab's Long-Term Investment Return: A 20-Year Analysis
- Riot Platforms: A Decade of Growth and Investment Potential
- XPO Announces Q3 2024 Earnings Call Details and Insights
- Maryland American Water's Acquisition Triumph Promises Reliability
- Know Labs Faces Compliance Challenges with NYSE American
- Ollie's Bargain Outlet Expands with Strategic Store Acquisitions
- Levi Strauss & Co Reports Q3 Earnings: A Closer Look at Results
- Exploring Bourbon Investment: CaskX Shines at Festival Event
- Aquaron Acquisition Corp. Secures Trust Account Funding for Deal
- Centerspace Acquires The Lydian and Updates Financials
- Penumbra, Inc. Plans Q3 2024 Earnings Call on October 30
- Radiant Logistics' Strategic Move: Acquisition of Focus Logistics
- F.N.B. Corporation Supports Hurricane Relief with $100,000 Donation
- Codexis Secures $31 Million to Propel Growth into 2027
- First Citizens BancShares Sets Date for Earnings Review Call
- Fidelity National Financial Expands Presence with Strategic Acquisition
- Polu Kai Services Secures Major Contract for Military Support
- Tesla Price Target Elevated: What Investors Should Know
- BigCommerce Welcomes Travis Hess as Its New Chief Executive
- Globus Medical Enhances Trauma Product Line with Innovations
- Certara Strengthens Drug Development with Chemaxon Acquisition
- Corner Growth Acquisition Corp. 2's Strategic Shift in Accounting
- Humana Faces Challenges as BofA Downgrades Outlook